Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials

Editorial

Justin J O'Hagan et al. AIDS. 2012.

. 2012 Jan 14;26(2):123-6.

doi: 10.1097/QAD.0b013e32834e1ce7.

No abstract available

Conflict of interest statement

Conflicts of Interest

JOH and MAH report no conflicts of interest.

Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial.
Grobler A, Abdool Karim S. Grobler A, et al. AIDS. 2012 Nov 13;26(17):2261; author reply 2262-3. doi: 10.1097/QAD.0b013e328355ce08. AIDS. 2012. PMID: 23123519 No abstract available.

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220. - PubMed
1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174. - PMC - PubMed
1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599. - PMC - PubMed
1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med. 2011;365:493–505. - PMC - PubMed
1. Centers for Disease Control Prevention. [Accessed July 20, 2011];TDF2 Press Release. Available from: http://www.cdc.gov/nchhstp/newsroom/PrEPHeterosexuals.html.